<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03627936</url>
  </required_header>
  <id_info>
    <org_study_id>APD356-A001-040</org_study_id>
    <nct_id>NCT03627936</nct_id>
  </id_info>
  <brief_title>A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants</brief_title>
  <official_title>A Randomized, Open-Label, Crossover Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen Under Fasted Conditions in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the bioequivalence between lorcaserin XR tablets
      manufactured in Kawashima and lorcaserin XR tablets manufactured in Zofingen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 7, 2018</start_date>
  <completion_date type="Actual">September 2, 2018</completion_date>
  <primary_completion_date type="Actual">September 2, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Lorcaserin</measure>
    <time_frame>predose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 24, 36, 48, 72, and 96 hours postdose in each treatment period; treatment period length = 4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from zero time to time of last quantifiable concentration (AUC [0-t]) of Lorcaserin</measure>
    <time_frame>predose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 24, 36, 48, 72, and 96 hours postdose in each treatment period; treatment period length = 4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from zero time extrapolated to infinite time (AUC [0-inf]) of Lorcaserin</measure>
    <time_frame>predose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 24, 36, 48, 72, and 96 hours postdose in each treatment period; treatment period length = 4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from zero time to 72 hour (AUC [0-72h]) of Lorcaserin</measure>
    <time_frame>predose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 24, 36, 48, and 72 hours postdose in each treatment period; treatment period length = 4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (tmax) of Lorcaserin</measure>
    <time_frame>predose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 24, 36, 48, 72, and 96 hours postdose in each treatment period; treatment period length = 4 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination phase half-life (tÂ½) of Lorcaserin</measure>
    <time_frame>predose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 24, 36, 48, 72, and 96 hours postdose in each treatment period; treatment period length = 4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With One or More Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)</measure>
    <time_frame>Baseline up to 28 days after last dose of study drug (Day 35)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Markedly Abnormal Laboratory Values</measure>
    <time_frame>Baseline up to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in Vital Signs Parameters</measure>
    <time_frame>Baseline, Day 1, Day 2, Day 6, Day 7, Day 8, and Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Findings in Physical examinations</measure>
    <time_frame>Baseline and Day 11</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Lorcaserin 20 mg manufactured at: Zofingen (A) + Kawashima (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of lorcaserin 20 milligram (mg) XR tablets manufactured at Zofingen (A) after a 10-hour overnight fast on Day 1 of treatment period 1 followed by a single oral dose of lorcaserin 20 mg XR tablet manufactured at Kawashima (B) after a 10-hour overnight fast on Day 7 of treatment period 2. A washout period of 5 days will be maintained between the 2 treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lorcaserin 20 mg manufactured at: Kawashima (B) + Zofingen (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single oral dose of lorcaserin 20 mg XR tablets manufactured at Kawashima (B) after a 10-hour overnight fast on Day 1 of treatment period 1 followed by a single oral dose of lorcaserin 20 mg XR tablet manufactured at Zofingen (A) after a 10-hour overnight fast on Day 7 of treatment period 2. A washout period of 5 days will be maintained between the 2 treatment periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin manufactured at Zofingen</intervention_name>
    <description>Lorcaserin XR tablets manufactured at Zofingen.</description>
    <arm_group_label>Lorcaserin 20 mg manufactured at: Kawashima (B) + Zofingen (A)</arm_group_label>
    <arm_group_label>Lorcaserin 20 mg manufactured at: Zofingen (A) + Kawashima (B)</arm_group_label>
    <other_name>BELVIQ XR</other_name>
    <other_name>APD356</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin manufactured at Kawashima</intervention_name>
    <description>Lorcaserin XR tablets manufactured at Kawashima.</description>
    <arm_group_label>Lorcaserin 20 mg manufactured at: Kawashima (B) + Zofingen (A)</arm_group_label>
    <arm_group_label>Lorcaserin 20 mg manufactured at: Zofingen (A) + Kawashima (B)</arm_group_label>
    <other_name>BELVIQ XR</other_name>
    <other_name>APD356</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-smoking, healthy participants at the time of informed consent.

          -  Body mass index (BMI) of 18 to 30 kilogram per square meter (kg/m^2) (inclusive) at
             Screening.

        Exclusion Criteria:

          -  Clinically significant illness that requires medical treatment within 8 weeks or a
             clinically significant infection that requires medical treatment within 4 weeks before
             first dosing.

          -  Evidence of disease that may influence the outcome of the study within 4 weeks before
             first dosing; eg, psychiatric disorders and disorders of the gastrointestinal tract,
             liver, kidney, respiratory system, endocrine system, hematological system,
             neurological system, or cardiovascular system, or participants who have a congenital
             abnormality in metabolism.

          -  History of drug or alcohol dependency or abuse within the 2 years before Screening, or
             those who have a positive urine drug, cotinine, or alcohol test at Screening or
             Baseline.

          -  Participants who contravene the restrictions on concomitant medications, food and
             beverages.

          -  Currently enrolled in another clinical study or used any investigational drug or
             device within 4 weeks preceding informed consent.

          -  Receipt of blood products within 4 weeks, or donation of blood within 8 weeks, or
             donation of plasma within 1 week of dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>October 16, 2018</last_update_submitted>
  <last_update_submitted_qc>October 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lorcaserin</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Extended release</keyword>
  <keyword>Tablets</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Healthy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

